Etanercept in the longterm treatment of patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 36, Issue 6, 2009, Pages 1256-1264

  Dijkmans, Ben ^h   Emery, Paul ^m   Hakala, Markku ^c,l   Leirisalo Repo, Marjatta ^b   Mola, Emilio Martin ^k   Paolozzi, Laurence ⁿ   Salvarani, Carlo ^f   Sanmarti, Raimon ^j   Sibilia, Jean ^d   Sieper, Joachim ^e   Van Den Bosch, Filip ^a   Van Der Heijde, Désirée ⁱ   Van Der Linden, Sjef ^g   Wajdula, Joseph ^o  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^m UNIVERSITY OF LEEDS   (United Kingdom)

ⁿ Clinical Research and Development   (France)

^o PFIZER INC   (United States)

more..

Author keywords

Ankylosing spondylitis; Assessment in ankylosing spondylitis 20; Etanercept; Modified stoke ankylosing spondylitis spine score

Indexed keywords

ANTIBIOTIC AGENT; ETANERCEPT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; BLOOD DYSCRASIA; BONE RADIOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INFECTION; INFECTIOUS DIARRHEA; INJECTION SITE REACTION; LARYNGITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; PAIN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SKIN INFECTION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67149115523     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081033     Document Type: Article

References (32)

1. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-1675 (Pubitemid 36682375)
2. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-3236 (Pubitemid 37409337)
3. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-1600 (Pubitemid 39573687)
4. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-1356 (Pubitemid 34754607)
5. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501. (Pubitemid 41278913)
6. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 2007;46:999-1004. (Pubitemid 47062511)
7. Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-352 (Pubitemid 351281269)
8. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368
9. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-1886 (Pubitemid 32758236)
10. van der Heijde D. ASsessment in ankylosing spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005;52:386-394 (Pubitemid 40216302)
11. Wanders AJ, Landewe RB, Spoorenberg A, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622-2632 (Pubitemid 39062724)
12. Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-129
13. Surveillance, Epidemiology, and End Results (SEER) program public-use data (1973-1999) [11 registries, 1992-1999)], National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission. Internet. Available at: http:www.seer.cancer.gov [Accessed April 13, 2009].
14. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-1562 (Pubitemid 41532037)
15. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other DMARDs (3-year interim report). Ann Rheum Dis 2006;65:1578-1584
16. Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2003;48:3230-3236 (Pubitemid 37409337)
17. Feltelius N, Ekbom A, Blomqvist P. Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-1995: a population based cohort study. Ann Rheum Dis 2003;62:1185-1188
18. Askling J, Klareskog L, Blomqvist P, Fored M, Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006;65:1184-1187 (Pubitemid 44277393)
19. Brophy S, Pavy S, Lewis P, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001;28:2667-2673 (Pubitemid 33135654)
20. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-1094 (Pubitemid 33022088)
21. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62:74-76 (Pubitemid 36005801)
22. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-647 (Pubitemid 46764055)
23. Wajdula J, Sridharan S, Fletcher T, MacPeek D, Meier E. Rates of IBD in patients receiving etanercept and placebo in AS. Arthritis Rheum 2007;56:S256-7.
24. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766-771 (Pubitemid 27348200)
25. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-2451 (Pubitemid 41117431)
26. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-1634 (Pubitemid 44799677)
27. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-3252 (Pubitemid 47585419)
28. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-1466 (Pubitemid 41623858)
29. van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-1331 (Pubitemid 351705922)
30. van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-3070
31. Schett G, Landewe R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007;66:709-711
32. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163 (Pubitemid 46245765)